The Hyderabad-based subsidiary of French drugmaker Sanofi Pasteur, Shantha Biotechnics announced that it will be resuming the supply of its pediatric pentavalent vaccine Shan5 to World Health Organization (WHO) programs across the world.
The supply had been stopped about the WHO highlighted certain issues with the vaccine and Shantha's non-executive chairman K.I. Varaprasad Reddy revealed that Sanofi had invested over 125 million euros in addressing the issues. Reddy added that the company hopes for annual earnings of Rs 500 crore following the resumption of supplies.
Shingles
In 'Shingles' or 'Herpes Zoster' painful skin rashes appear usually on the side of chest wall. It is caused by chicken pox virus called varicella zoster.
Advertisement
"We received a setback in 2010 due to sedimentation issues with the vaccines and WHO withdrew the prequalification in 2010. Losing the prequalification was indeed a pressure on us but now we have come out of it with a commitment for a better product. We have done the largest clinical trial of the vaccine with 1,100 infants and 11 medical school study centres across India", the CEO of Shantha Biotechnics, Harish Iyer said.
Source: Medindia
Tetanus
Tetanus (or Lockjaw) is a serious preventable infection that can affect the muscles and nerves and results from contamination of wound. The vaccine against Tetanus can prevent the infection.
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest General Health News
In India, youth must be aware of the diseases linked to cigarette smoking and tobacco consumption, causing a form of healthcare emergency.
Direct coastal access may represent a viable route to public health promotion, but the relationships of coastal living are not strongest among lower-income groups.
New research by Tinnitus UK has found that over four million gardeners are putting their hearing capacity at risk this summer without using safety protection.
Mucus plugs could be targeted to help reduce fatalities from chronic obstructive pulmonary disease.
The development of reliable curative therapies for multiple sclerosis could significantly reduce the economic burden of the disease on patients and wider society.